Malaria Vaccines Market is projected to accelerate at a CAGR of 27% from 2023 to 2032 | insightSLICE
The global Malaria Vaccines market size was estimated to be US$ 390 million in 2021 and is expected grow at a CAGR of 27% between 2023 to 2032.
Approximately half of the world’s population is at risk for malaria, according to statistics published by the World Health Organization (WHO). Because of this, numerous healthcare organizations now prioritize tackling this serious issue.
The Melinda Gates Foundation and PATH, among other non-profit groups, are attempting to create preventive strategies and save many lives in malaria-affected areas. Africa has the highest number of reported cases of malaria; hence GlaxoSmithKline plc’s innovative malaria vaccine is being introduced with a focus on this continent.
Access the sample report: https://www.insightslice.com/request-sample/84
Mosquirix received European approval in 2015, and a pilot study is presently being conducted there. To protect themselves against malarial vectors, Africans use insecticide-treated mosquito repellent as well as interior insecticide spraying. Between 2010 and 2015, the use of insecticide-treated mosquito nets surged by 80% across Africa.
The key players of the Global Malaria Vaccines Market are:
The major companies that provide malaria vaccines include Sanaria Inc, Sumaya Biotech, GlaxoSmithKline Plc, Nobelpharma Co., Ltd., and GenVec Inc,
Available treatment options and their shortcomings:
A variety of mosquito-repelling items, including coils, patches, mats, creams, liquids, and others, are sold all over the world. The non-profit groups are also involved in offering low-cost and free treatment options to those in Africa who are suffering from malaria.
Additionally, GSK has considered offering the vaccines at a lesser price while forgoing its substantial profit margins in order to help global malaria eradication initiatives. The market for malaria vaccines is anticipated to expand in the future since there are more malaria vaccines in the pipeline for development.
Due to a growing emphasis on biological preparations, there is a strong demand for vaccinations for serious diseases, which is one of the factors driving the growth of the malaria vaccine market.
Additionally, numerous governments from other nations as well as businesses and non-profit groups are working to stop the spread of this disease. Programs aimed at reducing malaria are heavily supported by administrations in various countries.
The World Health Organization (WHO) withdrew funds from the Global Fund for the first phase of a pilot program to fight malaria and other diseases like AIDS and tuberculosis that are widespread around the world between 2017 and 2020.
The World Health Organization (WHO) announced a global technical plan for malaria from 2016 to 2030 in 2015. One of the main objectives was to eradicate malaria in at least 10 nations.
The Indian government has acknowledged several Fever Treatment Depots (FTDs) and Drug Distribution Centers (DDCs) for providing simple access to anti-malarial medications in rural areas. To lower malaria infection, a number of government measures are under constant review and monitoring.
The expansion of the market for malaria vaccines in the coming years will be fueled by this kind of assistance from these national and international initiatives.
Read more about the report inclusions: https://www.insightslice.com/malaria-vaccines-market
Major market segments and their growth forecast:
Due to the increasing incidence of Plasmodium falciparum malaria, is anticipated to fuel market expansion throughout the projected period. The Plasmodium Falciparum sector from the Agent-based segmentation is anticipated to maintain a dominating position in the global malaria vaccine market in 2022.
For instance, Plasmodium Falciparum infection is responsible for more than 90% of malaria fatality worldwide, according to data from the National Center for Biotechnology Information published in August 2021.
This suggests that the P. falciparum malarial infection is one of the most serious threats to the public health across many countries around the world.
The pre-erythrocytic segment is anticipated to have a dominant share in the worldwide malaria vaccine market during the projected period based on vaccine type. This marked growth is owing to an increase in the number of malaria vaccine launches in the forecasted period.
For instance, in October 2021, the science-driven global healthcare company GlaxoSmithKline announced that children in sub-Saharan Africa and other areas with moderate to severe malaria incidence can now access the company’s RTSS vaccine, which protects against Plasmodium falciparum, the most lethal malaria parasite in the world and the most common in Africa.
Global Bio absorbable Stents Market: https://www.insightslice.com/bio-absorbable-stents-market
Global Artificial Lungs Market: https://www.insightslice.com/artificial-lungs-market
Global Malaria Vaccines Market Key Segments:
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
By Vaccine Type
By Distribution Channel
- North America
- United States
- Rest of North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- South America
- Rest of South America
Regional performance of Malaria Vaccines Market
During the projection period, it is expected that the North American region will dominate the market for malaria vaccines and have the largest market share. However, due to their enormous patient populations, the Asia-Pacific and Middle Eastern regions are predicted to increase quickly during the forecast period.
Proceed to purchase: https://www.insightslice.com/buy-now/84
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at email@example.com.
+1 707 736 6633